- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human epidermal growth factor 2 (HER2) negative metastatic breast cancer with a confirmed BRCA1 or BRCA2 mutation
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 470KB)
Olaparib – July 2024
Olaparib; Tablet 100 mg, Tablet 150 mg; Lynparza®
Last updated
30 May 2025